Psilera
Psilera is a biotech research company founded in 2019, specializing in early-stage drug discovery and development of next-generation neuroplastogens for neurological disorders. The company focuses on creating patient-centric therapies, particularly for hard-to-treat conditions like Frontotemporal Dementia (FTD), with an emphasis on non-hallucinogenic compounds. Psilera leverages its proprietary Third Eye™ drug screening platform to analyze compound interactions with the brain, aiming to improve quality of life for patients suffering from cognitive diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Products
PSIL-006
A next-generation psilocybin-derivative small-molecule candidate designed for treatment of frontotemporal dementia; described as non-hallucinogenic in preclinical studies with reported activity at serotonin 5-HT2A and single-dose efficacy in animal models.
PSIL-006
A next-generation psilocybin-derivative small-molecule candidate designed for treatment of frontotemporal dementia; described as non-hallucinogenic in preclinical studies with reported activity at serotonin 5-HT2A and single-dose efficacy in animal models.
Services
Lead identification, medicinal chemistry, and preclinical advancement of small-molecule candidates for neurological indications.
Preclinical testing using animal behavioral models and external organ-on-a-chip platforms to evaluate candidate efficacy and mechanism.
Lead identification, medicinal chemistry, and preclinical advancement of small-molecule candidates for neurological indications.
Preclinical testing using animal behavioral models and external organ-on-a-chip platforms to evaluate candidate efficacy and mechanism.
Expertise Areas
- Early-stage drug discovery and development
- Medicinal chemistry for serotonergic small molecules
- Neuropsychiatric and neurodegenerative disease-focused R&D
- Computational chemistry and predictive modeling
Key Technologies
- Computational chemistry and in silico screening
- Machine learning / data-driven predictive modeling
- Large-scale compound library design
- Animal behavioral models for neurological disorders
News & Updates
Psilera collaborates with drug development leader Hesperos to enhance preclinical modeling of PSIL-006 for FTD.
Psilera announced positive preclinical in vivo data for its FTD candidate PSIL-006.
An article discussing the involvement of drug companies in the psychedelic industry, highlighting Psilera's role.
An article exploring scientific efforts to improve psychedelic experiences, mentioning Psilera's research.
Research on non-hallucinogenic psychedelics, including Psilera's developments.
Coverage of the growing investment in psychedelic biotech companies like Psilera.
Psilera collaborates with drug development leader Hesperos to enhance preclinical modeling of PSIL-006 for FTD.
Psilera announced positive preclinical in vivo data for its FTD candidate PSIL-006.
An article discussing the involvement of drug companies in the psychedelic industry, highlighting Psilera's role.
An article exploring scientific efforts to improve psychedelic experiences, mentioning Psilera's research.
Research on non-hallucinogenic psychedelics, including Psilera's developments.
Coverage of the growing investment in psychedelic biotech companies like Psilera.